272 related articles for article (PubMed ID: 33437354)
1. Immunotherapeutic strategies for sarcoma: current perspectives.
Li X; Wang G; Cai Z; Sun W
Am J Transl Res; 2020; 12(12):7693-7701. PubMed ID: 33437354
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
4. New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype.
Lim J; Poulin NM; Nielsen TO
Clin Cancer Res; 2015 Nov; 21(21):4753-9. PubMed ID: 26330427
[TBL] [Abstract][Full Text] [Related]
5. Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapies in sarcoma: Updates and future perspectives.
Ghosn M; El Rassy E; Kourie HR
World J Clin Oncol; 2017 Apr; 8(2):145-150. PubMed ID: 28439495
[TBL] [Abstract][Full Text] [Related]
7. Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities.
Jeong S; Afroz S; Kang D; Noh J; Suh J; Kim JH; You HJ; Kang HG; Kim YJ; Kim JH
Mol Cells; 2023 Oct; 46(10):579-588. PubMed ID: 37853684
[TBL] [Abstract][Full Text] [Related]
8. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT; Shenasa E; Nielsen TO
Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
[TBL] [Abstract][Full Text] [Related]
9. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.
Tang F; Tie Y; Wei YQ; Tu CQ; Wei XW
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188606. PubMed ID: 34371128
[TBL] [Abstract][Full Text] [Related]
10. Emerging Targeted and Immune-Based Therapies in Sarcoma.
Pollack SM; Ingham M; Spraker MB; Schwartz GK
J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
[TBL] [Abstract][Full Text] [Related]
11. Role of Immunotherapy in Sarcomas.
Dalal S; Shan KS; Thaw Dar NN; Hussein A; Ergle A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279265
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic approaches to sarcoma.
Burgess M; Tawbi H
Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Bone and Soft Tissue Sarcomas.
Uehara T; Fujiwara T; Takeda K; Kunisada T; Ozaki T; Udono H
Biomed Res Int; 2015; 2015():820813. PubMed ID: 26167500
[TBL] [Abstract][Full Text] [Related]
14. Immuno-Oncology: Emerging Targets and Combination Therapies.
Marshall HT; Djamgoz MBA
Front Oncol; 2018; 8():315. PubMed ID: 30191140
[TBL] [Abstract][Full Text] [Related]
15. Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy?
Atherton MJ; Lenz JA; Mason NJ
Vet Comp Oncol; 2020 Dec; 18(4):447-470. PubMed ID: 32246517
[TBL] [Abstract][Full Text] [Related]
16. Emerging trends in immunotherapy for pediatric sarcomas.
Dyson KA; Stover BD; Grippin A; Mendez-Gomez HR; Lagmay J; Mitchell DA; Sayour EJ
J Hematol Oncol; 2019 Jul; 12(1):78. PubMed ID: 31311607
[TBL] [Abstract][Full Text] [Related]
17. Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
Ozaniak A; Vachtenheim J; Lischke R; Bartunkova J; Strizova Z
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440139
[TBL] [Abstract][Full Text] [Related]
18. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Ă–zdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
19. From vision to reality: deploying the immune system for treatment of sarcoma.
Wilky BA; Goldberg JM
Discov Med; 2017 Jan; 23(124):61-74. PubMed ID: 28245428
[TBL] [Abstract][Full Text] [Related]
20. Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?
Chew HY; Chan V; Simpson F; Dolcetti R
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]